The First Edition of MicroPort® Master Course Complex PCI Cross-Regional Program Ends Successfully
Tianjin, China- From February 20 to 23, 2019, the Master Course Complex PCI Cross-Regional Program ("the Master Course") - Cross-Strait Academic Exchange Session ("the Session"), which was hosted by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), took place in Tianjin and Yantai of China. The Session, which was the first edition of the Master Course, invited Prof. Tien-Ping Tsao, who is a renowned interventional cardiologist in Taiwan, China, to demonstrate live surgeries and give instructions. The Session is aimed at the enhancement of scientific exchanges between the cross-strait interventional cardiologists and improve the PCI treatment in Tianjin and Yantai.
Prof. Tien-Ping Tsao is currently head of the Cardiac Intensive Care Center of Cheng Hsin General Hospital in Taiwan and also sits on the Education Committee and Structural Heart Diseases Committee of Taiwan Society of Cardiovascular Interventions (TSCI). He is a very experienced cardiovascular interventionalist with deep insight into PCI treatment, especially excelling at the PCI treatment of coronary chronic total occlusion. In addition, he has taken part in several scientific exchanges both on the mainland and in Taiwan.
From February 20 to 21, the Session was unveiled at Tianjin Medical University General Hospital. Prof. Tien-Ping Tsao worked with the PCI team from the Cardiology Department of the hospital to demonstrate live surgeries for the PCI treatment of complex lesions such as chronic total occlusion (CTO) and left main bifurcation. From February 22 to 23, the Session moved to Yantai, where he demonstrated live surgeries and gave surgical instructions to the Cardiology Department of Yantai Yuhuangding Hospital and the PCI team from the Cardiology Department of Yantai Yantaishan Hospital respectively, and successfully completed the PCI treatment for coronary CTO and bifurcation lesions. During the surgeries, the local physicians and Prof. Tien-Ping Tsao had heated exchanges and discussions about surgical details. All the surgeries progresses smoothly, with the patients having good recoveries. As top-tier hospitals certified by China Chest Pain Center, all the cardiology departments of the above three hospitals involved in the Session have rich experience in PCI treatment. The successful interventional treatment of the high-risk and challenging CTO fully reflected the excellent surgical capability and leading skills of the cross-strait healthcare professionals in the field of complex lesion PCI treatment.
The Master Course is a new branded academic exchange that MicroPort® introduces in 2019. It is aimed to promote the scientific exchanges on PCI between different Chinese regions, cross-strait regions and the Asia-Pacific countries and regions with a series of Cross-Regional programs. Prof. Tien-Ping Tsao said: "The first edition of the Master Course has provided an excellent communication platform for the cross-strait PCI healthcare professionals, who learned a lot in scientific discussions and communications during the surgeries." MicroPort® First Vice President, Domestic Coronary Sales & Marketing, Lei Jiang commented, "We expect to create an expert lecturer team for PCI treatment, which is exclusive to MicroPort®, with a series of activities under the Master Course, so as to have the influence of MicroPort® in the Asia-Pacific PCI area grow further. Meanwhile, we hope to drive continuous innovation in product R&D and application with the inspirations generated during the exchanges among the healthcare professionals, to produce more innovative high-end medical device products and benefit the patients globally."
MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.
Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.
This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.
Copyright © 1998-2018 MicroPort Scientific Corporation. All rights reserved.
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6957
[Prev]：MicroPort® Receives CE Mark for Firehawk Liberty™, a New Generation Rapamycin Target Eluting Coronary Stent System
[Next]：MicroPort® CardioFlow Attends CSI Asia-Pacific 2019